Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiarui Li

Showing results (491-500 of 493) with videos related to

Pageof 50
Sort By:
You have reached the last page of results.This site can display upto 493 results.
Cell Reports|January 4, 2022
Two-step fitness selection for intra-host variations in SARS-CoV-2Jiarui Li, Pengcheng Du, Lijiang Yang, et al.
Diabetologia|March 9, 2021
Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled studyLinong Ji, Ying Du, Min Xu, et al.
JAMA Oncology|December 30, 2021
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019, Jonathan M Kocarnik, Kelly Compton, et al.
Pageof 50

Showing results (491-500 of 493) with videos related to

Sort By:
Pageof 50
You have reached the last page of results.This site can display upto 493 results.
Cell Reports|January 4, 2022
Two-step fitness selection for intra-host variations in SARS-CoV-2Jiarui Li, Pengcheng Du, Lijiang Yang, et al.
Diabetologia|March 9, 2021
Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled studyLinong Ji, Ying Du, Min Xu, et al.
JAMA Oncology|December 30, 2021
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019, Jonathan M Kocarnik, Kelly Compton, et al.
Pageof 50